高血压和轻度认知障碍:最先进的技术审查
Sultana Shajahan1, Ruth Peters1, Cheryl Carcel1,2
1Brain Health Program, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
American journal of hypertension
|January 12, 2024
概括
中年高血压会增加痴呆症的风险. 虽然血压控制可能有帮助,但对老年人和轻度认知障碍 (MCI) 患者需要更多的研究.
科学领域:
- 神经学 神经学
- 老年学是一门学科.
- 心脏病学 心脏病学
背景情况:
- 中年高血压是已知的认知能力下降和晚年痴呆的风险因素.
- 抗高血压疗法是预防痴呆症和轻度认知障碍 (MCI) 的潜在策略.
- 支持抗高血压治疗的证据有限,特别是对于非常老人和现有MCI的人来说.
研究的目的:
- 审查目前关于高血压和MCI之间的联系的证据.
- 探索连接高血压,认知衰退和衰老中的痴呆症的病理生理机制.
主要方法:
- 对观察数据和临床试验证据的系统审查.
- 对研究中年,年轻人和非常老 (>80岁) 的人高血压的分析.
- 对抗高血压药物在预防痴呆和MCI方面的疗效的评估.
主要成果:
- 观察性研究始终将中年高血压与MCI和痴呆症联系起来.
- 对高血压对年轻人和老年人的影响的证据不那么广泛.
- 大多数抗高血压药物在降低痴呆风险方面显示出潜在的益处,但治疗现有的MCI的证据有限.
结论:
- 最佳的血压目标和有效的抗高血压药物用于认知维护需要在不同年龄组进行进一步的研究,特别是在患有MCI的成年人中.
- 需要更多的研究来指导高血压的治疗策略,在有风险的人群和那些已建立的MCI.
相关概念视频
Cognitive Development During Adulthood
112
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
112
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
126
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
126
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


